Literature DB >> 20839067

Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC).

Doran Ksienski1, Ryan Woods, Caroline Speers, Hagen Kennecke.   

Abstract

BACKGROUND: Rates of metastatectomy vary among patients with liver-only metastatic colorectal cancer (MCRC). This study describe predictors of referral to a hepatobiliary surgeon (HBS) and hepatic resection in a population-based setting.
MATERIALS AND METHODS: Patients referred to the British Columbia Cancer Agency (BCCA) with synchronous or relapsed MCRC isolated to the liver in 2002-2004 were identified. Classification of tumor burden as "high" or "low" was based on prognostic features defined by LiverMetSurvery registry. Metastases larger than 5 cm, bilobar, or more than 3 metastases were classified as high tumor burden. Multivariate logistic regression models were used to identify predictors of HBS referral and subsequent metastatectomy. Overall survival was calculated by the Kaplan-Meier method.
RESULTS: Of 618 patients with isolated hepatic metastasis, 148 (24%) were referred to a HBS and 99 (16%) underwent resection. Advanced age was the most common reason for not referring 64 patients (10%) with ECOG performance status 0/1 and low tumor burden. In multivariate analysis, variables associated with referral were younger age (P < .001), ECOG performance status 0/1 (P < .002), chemotherapy for metastatic disease (P = .007), 1-3 metastasis (P < .001), and unilobar disease (P < .001). Median patient survival was 0.99 years (95% confidence interval [95% CI], 0.89-1.10 years) among nonreferred, 1.83 years (95% CI, 1.37-2.31 years) if referred but not resected, and 3.85 years (95% CI, 2.90-4.80 years) if resected.
CONCLUSION: A significant proportion of patients are not referred to a HBS because of advanced chronological age. Resection of hepatic metastases was associated with improved overall survival irrespective of initial tumor burden.

Entities:  

Mesh:

Year:  2010        PMID: 20839067     DOI: 10.1245/s10434-010-1304-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Variation in hospital treatment patterns for metastatic colorectal cancer.

Authors:  Robert W Krell; Scott E Regenbogen; Sandra L Wong
Journal:  Cancer       Date:  2015-01-29       Impact factor: 6.860

2.  Morbidity, mortality, and survival in elderly patients undergoing pulmonary metastasectomy for colorectal cancer.

Authors:  S Sponholz; Moritz Schirren; Selma Oguzhan; Joachim Schirren
Journal:  Int J Colorectal Dis       Date:  2018-07-28       Impact factor: 2.571

3.  Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study.

Authors:  S Yousuf Zafar; Jennifer L Malin; Steven C Grambow; David H Abbott; Jane T Kolimaga; Leah L Zullig; Jane C Weeks; John Z Ayanian; Katherine L Kahn; Patricia A Ganz; Paul J Catalano; Dee W West; Dawn Provenzale
Journal:  Cancer       Date:  2012-09-12       Impact factor: 6.860

4.  Surgical Referral for Colorectal Liver Metastases: A Population-Based Survey.

Authors:  Robert W Krell; Bradley N Reames; Samantha Hendren; Timothy L Frankel; Timothy M Pawlik; Mathew Chung; David Kwon; Sandra L Wong
Journal:  Ann Surg Oncol       Date:  2015-01-13       Impact factor: 5.344

5.  The Impact of a Hepatobiliary Multidisciplinary Team Assessment in Patients with Colorectal Cancer Liver Metastases: A Population-Based Study.

Authors:  Jennie Engstrand; Nikolaos Kartalis; Cecilia Strömberg; Mats Broberg; Anna Stillström; Tobias Lekberg; Eduard Jonas; Jacob Freedman; Henrik Nilsson
Journal:  Oncologist       Date:  2017-05-26

Review 6.  Multisciplinary management of patients with liver metastasis from colorectal cancer.

Authors:  Kathleen De Greef; Christian Rolfo; Antonio Russo; Thiery Chapelle; Giuseppe Bronte; Francesco Passiglia; Andreia Coelho; Konstantinos Papadimitriou; Marc Peeters
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

7.  Impact of liver-directed therapy in colorectal cancer liver metastases.

Authors:  Gabriela M Vargas; Abhishek D Parmar; Kristin M Sheffield; Nina P Tamirisa; Kimberly M Brown; Taylor S Riall
Journal:  J Surg Res       Date:  2014-06-04       Impact factor: 2.192

8.  Use of chemotherapy and radiofrequency ablation to treat colorectal cancer metastases: a retrospective review of The Ottawa Hospital Cancer Centre over 7 years.

Authors:  N Boame; G Gresham; D Jonker; G Martel; F Balaa; T Asmis
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

9.  Time-to-Surgery and Survival Outcomes in Resectable Colorectal Liver Metastases: A Multi-Institutional Evaluation.

Authors:  Julie N Leal; Alexsander K Bressan; Neeta Vachharajani; Mithat Gonen; T Peter Kingham; Michael I D'Angelica; Peter J Allen; Ronald P DeMatteo; Majella B M Doyle; Oliver F Bathe; Paul D Greig; Alice Wei; William C Chapman; Elijah Dixon; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2016-01-30       Impact factor: 6.113

10.  Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatment.

Authors:  K Homayounfar; A Bleckmann; L C Conradi; T Sprenger; T Beissbarth; T Lorf; M Niessner; C O Sahlmann; J Meller; H Becker; T Liersch; B M Ghadimi
Journal:  Int J Colorectal Dis       Date:  2012-03-21       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.